A retrospective, multicenter study of durvalumab in stage III non-small cell lung cancer patients after chemoradiotherapy
Latest Information Update: 19 Feb 2021
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary) ; Afatinib; Erlotinib; Gefitinib; Osimertinib
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2021 New trial record
- 12 Feb 2021 Results published in the Journal of Thoracic Oncology